We also demonstrated that our system is capable of imaging a minor population of cancer stem cells, CD133+ CTCs, which are found in 0.7% of pancreatic cancer cells and 1%–3% of solid tumors in patients. This evidence concerns the gene PROM1 and pancreatic neoplasm.